Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | MicrobiomeTrials← Back to trialsNCT04322383
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-01-07Est. Completion: 2028-04-30
Enrollment target: 40 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Hairy Cell LeukemiaHairy Cell Leukemia VariantRecurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned aft…
Bethesda, United StatesEst. completion Dec 31, 2029
Hairy Cell Leukemia
Background:
Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene m…
Bethesda, United StatesEst. completion May 20, 2026